The Drug That Got Pulled Not for Being Dangerous, but for Lying

The New England Journal of Medicine retracted the pivotal paper after the two lead academic authors requested it, acknowledging that the post-lock re-adjudication was never disclosed in the article.

The FDA Saw the Same Thing

Europe wasn't alone. Back on April 27, 2026, the FDA proposed withdrawing U.S. approval too. The agency said new information showed that unblinded study personnel manipulated the results so the drug appeared effective, and that the original analysis was never disclosed to the FDA, violating federal regulations.

As of early June, Amgen said Tavneos remains FDA-approved and available in the U.S. while the process plays out. The company disagrees with regulators on both sides of the Atlantic, arguing the totality of evidence supports the drug's benefit-risk profile. But the trajectory here is clear: both major regulators are pointing at the same data problems.

Why This Almost Never Happens

Drugs get pulled from markets more often than you'd think, but almost always for safety reasons. A nasty side effect shows up in the real world that trials missed. A manufacturing problem emerges. Those are the standard playbooks.

Pulling a drug because the clinical trial behind it was fraudulently conducted? That's extraordinarily rare for an already-marketed product. The EMA has refused applications and forced companies to withdraw submissions over GCP problems before. In 2020 alone, three centralized marketing applications were pulled due to GCP non-compliance. But those drugs never made it to pharmacy shelves.

Tavneos did. It was approved by the FDA in October 2021 and prescribed to real patients with ANCA-associated vasculitis, a condition where the immune system attacks small blood vessels and can damage kidneys and lungs. These are patients who genuinely need better treatment options. Now the EMA is recommending that no new patients start treatment and that existing patients switch to alternatives.

The Financial Fallout (Smaller Than You'd Think)

For a company Amgen's size, Tavneos is a rounding error. The drug brought in $459 million in 2025, with a full 92% of those sales coming from the U.S. The EU withdrawal removes only a sliver of total revenue.

BMO Capital Markets called the NEJM retraction an "incremental negative" rather than a thesis-changing event, noting Tavneos is "not large enough to materially alter Amgen's consolidated growth outlook." The stock barely flinched: shares pared earlier gains on the news day but still closed up 0.3%.

The bigger financial question is an accounting one. Amgen carried about $2.4 billion in intangible assets tied to Tavneos at the end of March, a legacy of its 2022 acquisition of ChemoCentryx, the biotech that originally developed the drug. About $2.3 billion of that is linked to U.S. market expectations. If U.S. approval also falls, those asset values could face significant impairment charges.

Guggenheim Securities had already trimmed long-term Tavneos sales forecasts before the EU decision, suggesting some of the downside was priced in. But "priced in" and "resolved" are very different things.

The Bigger Picture: Trust Is the Product

In 2024, the EMA conducted 67 GCP inspections and found 335 major and critical deficiencies, including 11 critical findings.

The regulatory system caught the Tavneos problem, yes, but only after the drug had been on the market for years. Patients took it. Doctors prescribed it based on a published trial in the NEJM that turned out to be built on manipulated data.

The entire clinical trial system runs on trust: trust that sponsors lock their databases honestly, trust that unblinded personnel stay away from efficacy analyses, trust that what gets submitted to regulators reflects what actually happened. When that trust breaks down, the consequences ripple far beyond one drug.

Amgen will survive this. Tavneos was never going to make or break a company with dozens of blockbuster products. But for the rare disease patients who were counting on it, and for everyone who wants to believe that "FDA-approved" and "EMA-authorized" actually mean something, the damage is harder to measure.

When the FDA Commissioner Tries to Kill a Drug Himself

Reports claim FDA Commissioner Marty Makary personally tried to block KalVista's rare disease drug, an almost unprecedented intervention that raises uncomfortable questions about political influence at the agency. The drug got approved anyway, but the fallout is just beginning.